Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ...

For LDL-C levels below 55 mg/dL there was an 18% risk reduction for both all-cause dementia and ADRD. In those with LDL-C ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 ...

Pomegranate extract shows promise in lowering systolic blood pressure and inflammatory markers, highlighting its role in ...

Though high cholesterol may contribute to the risk of developing Alzheimer’s disease or a related dementia (ADRD), taking a ...

Adults with high or even low levels of LDL (bad) cholesterol who took statins lowered their risk of dementia in a new study.

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...

Because the trial ended up being underpowered, it did not show a benefit of intensive medical treatment, but there was a high ...